Scipher Medicine and Maxymune Therapeutics Partner to Speed Autoimmune and Inflammatory Disease Target Discovery

Scipher Medicine, known for its AI-driven precision immunology platform, has announced a strategic collaboration with Maxymune Therapeutics, a biotech company focused on novel treatments for immunological disorders. The partnership will see Maxymune utilizing Scipher’s advanced target ranking and engagement optimization tools to enhance its research and development efforts.

Through this collaboration, Scipher will provide Maxymune with customized target-ranking reports that integrate multi-omics disease models to evaluate the efficacy of protein targets. This data-driven approach aims to help Maxymune prioritize promising therapeutic targets and streamline development in autoimmune and inflammatory disease areas.

Dr. Reg Seeto, CEO of Scipher Medicine, emphasized the potential of their platform to reduce risks in drug development by identifying the most viable targets through detailed molecular network analysis. Maxymune’s COO, Tatjana Naranda, highlighted how combining Scipher’s AI insights with their biological research will accelerate the discovery of transformative immunotherapies.

This partnership underscores the increasing role of AI and data analytics in improving early-stage target identification and boosting the chances of clinical success in complex immune-mediated diseases.